Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the ...

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of ...

By Bhanvi Satija LONDON, Feb 2 (Reuters) - French drugmaker Sanofi said on Monday that its experimental genetic disorder ...

Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher diseaseIn the LEAP2MONO phase 3 study, venglustat, dosed ...

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of ...

The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

Sanofi halts plan mRNA seasonal flu vaccine, stopping phase 1 trial but continues work on mRNA pandemic flu vaccine with promising data.

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from ...

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...

By Bhanvi Satija LONDON, Jan 29 (Reuters) - France's Sanofi, among the world's largest vaccine makers, said on Thursday that its vaccines sales would be "slightly negative" this year, partly due to U.